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1. Introduction 
(-)-Deprenyl (D)/Selegiline, introduced under the code name: E-250, in 1964/65 as a new 
spectrum "psychic energizer" (Knoll et al., 1965), and named (-)-deprenyl from 1970, became 
famous in 1971/1972 as the first selective inhibitor of B-type monoamine oxidase (MAO-B) 
(Knoll  Magyar, 1972). D, registered at present in 64 countries, started its world-wide 
carrier as a therapeutic agent in 1977 as the unique MAO inhibitor free of the cheese-effect 
(reviewing its early history see Knoll, 1983).  
In the early 1960s when Knoll developed D MAO inhibitors were at the center of interest. It 
was the period when the hypothesis that depression is associated with diminished 
monoaminergic tone in the brain took root in the scientific community. MAO inhibitors 
played a key role in the development of this hypothesis. It became clear that MAO inhibitors 
elated depressed patients because they enhance the biological activity of monoamine 
transmitters in the central nervous system. 
In 1951 isoniazid and its isopropyl-derivative, iproniazid, were successfully introduced for 
the treatment of tuberculosis and it was an unexpected observation that in contrast to 
isoniazid, iproniazid produced undesirable central stimulation in some patients. Zeller, who 
proposed in 1938 the name “monoamine oxidase” for the class of enzymes responsible for 
the oxidative deamination of monoamines, discovered in 1952 that iproniazid is capable to 
inhibit MAO activity in the brain and isoniazid is devoid of this property (Zeller  Barsky, 
1952). In 1956 Crane analyzed the psychiatric side effects of iproniazid and concluded that it 
might be beneficial in the treatment of depression (Crane, 1956) and Kline introduced it as a 
“psychic energizer” (Kline, 1958).  
Series of new MAO inhibitors were soon developed. It was, however, observed in 1963 that 
after eating cheese depressive patients treated with the highly potent MAO inhibitor, 
tranylcypromine, develop temporary clinical symptoms similar to a paroxysm induced by 
pheochromocytoma: hypertension, palpitation, neck stiffness, headache, nausea, vomiting. 
The same was observed also during treatment with nialamid, pargyline, and other MAO 
inhibitors. Blackwell (1963) realized that the hypertensive crisis is associated with the 
ingestion of high amounts of tyramine in cheese, the metabolism of which is inhibited by the 
MAO inhibitors (“cheese-effect”). Similar clinical episodes have also been observed after the 
ingestion of some other foodstuffs, such as yeast products and chianti wines, pickled 
herring, chicken liver, which are rich in tyramine, and/or other amine such as  
-phenylethylamine (PEA), tryptamine, or L-3,4-dihydroxyphenylalanine (L-DOPA). 
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Knoll et al. demonstrated in a paper published in 1968 that the new MAO inhibitor, E-250, is 
free of the cheese-effect, because in contrary to the known MAO inhibitors, it does not 
potentiate, but inhibits the effect of tyramine (Knoll et al., 1968). The summary of this paper 
concluded that: “As the so-called cheese reaction, namely clinical symptoms similar to a 
paroxism induced by pheochromocytoma after cheese consumption is caused by the tyramine 
potentiating action of the MAO inhibitors, this tyramine inhibiting property of E-250 may be 
highly valuable for human therapy.” Following Knoll’s proposal it was shown later that D is 
free of the cheese effect also in humans (Elsworth et al., 1978; Sandler et al., 1978).  
It was Birkmayer in Vienna who first demonstrated that, in contrast to the known MAO 
inhibitors, D can be combined safely with levodopa in Parkinson’s disease (PD). Because of the 
serious side effect of levodopa in PD, Birkmayer and Hornykiewicz tried earlier to achieve a 
levodopa-sparing effect by the concurrent administration of levodopa and an MAO inhibitor, 
but this line of clinical research was soon terminated because the combination elicited serious 
hypertensive attacks (Birkmayer  Hornykiewicz, 1962). Birkmayer, considering the peculiar 
pharmacological profile of D dared to combine this MAO inhibitor with levodopa in PD and 
since the levodopa-sparing effect was achieved without side-effect (Birkmayer et al., 1977), this 
study initiated, and the Lancet Editorial “Deprenyl in Parkinson’s disease” (The Lancet, 
September 25, 1982) substantially promoted the worldwide use of D in PD. Further studies 
revealed that D slows the rate of the functional deterioration of the nigrostriatal dopaminergic 
neurons in patients with early, untreated PD, and thus slows the progress of the disease 
(Tetrud  Langstone, 1989; Parkinson Study Group, 1989, 1993; Allain et al., 1991; Myttyla et 
al., 1992; Larsen et al., 1999). 
The first two studies to demonstrate the beneficial effect of D in Alzheimer’s disease (AD) 
were published in 1987 (Martini et al., 1987; Tariot et al., 1987) and a stream of clinical 
studies with small sample sizes, published between 1990 and 1993, confirmed the usefulness 
of D in the treatment of the disease (for review see Knoll, 2001). Finally, in 1977 a proper 
controlled trial showed that in patient with moderately severe AD, treatment with D slows 
the progression of the disease (Sano et al., 1997).  
In retrospect it is hard to understand why D was before 2006, thus for 40 years, in striking 
contrast with the expectation of its developer, nowhere in the world registered with the 
indication to use it as an antidepressant. Knoll selected E-250 for further development in the 
hope that it will be used as a new efficient antidepressant. Before publishing the first paper 
on E-250 he already asked his schoolmate, the psychiatrist Ervin Varga, to test the new 
compound in depressed patients. The outcome of this preliminary study was cited as 
personal communication in the first paper (Knoll et al., 1965). Varga presented his results in 
the same year in a lecture (Varga, 1965) and published with his coworkers two papers on the 
antidepressant effect of D (Varga  Tringer, 1967; Tringer et al., 1971). Further clinical 
studies confirmed the antidepressant effect of D (Mann  Gershon, 1980; Youdim, 1980; 
Tom  Cummings, 1998; Zesiewitz et al., 1999; Miyoshi, 2001) and an analysis of the use of 
D in major depression was carefully reviewed (Gaszner  Miklya, 2006), nevertheless, only 
40 years after Knoll’s original proposal in 2006 was a D preparation (Emsam), based on a 
double-blind placebo-controlled trial performed by Amsterdam (2003), registered in the 
USA for the treatment of major depression. Emsam is the first transdermally administered 
antidepressant.  
Slowing the age-related deterioration of the catecholaminergic neurons is that still 
unexploited pharmacological property of D which deserves from practical point of view 
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favored attention. Although liquid deprenyl citrate preparations (Selepryl, Cyprenil) 
containing 1 mg D in 1 drop, the proposed daily dose for slowing brain aging, are since 
years in circulation, a controlled, double-blind clinical trial to lay the firm foundation of the 
prophylactic antiaging D therapy remained up to the present unperformed. 
Since the estimated increase of the number of individuals over 65 will reach by 2050 the 1.1 
billion level, thus to decrease the prevalence of age-related neurodegenerative diseases, like 
Parkinson’s and Alzheimer’s, is an urgent necessity, the main aim of this review is to sum 
up the arguments which renders probable the concept that the prophylactic lifelong daily 
administration of 1 mg D from sexual maturity until death improves the quality of life in 
senescence and show promise to prevent or delay the onset of PD and AD (Knoll, 2005).  
2. The development of deprenyl 
Joseph Knoll developed D in the early 1960s. Since 1951 he performed with his two 
coworkers, Karoly Kelemen and Berta Knoll, behavioral studies with rats, the aim of which 
was to study the cortical mechanisms which ensure the manipulability of the individual. He 
essentially developed in those years his working hypothesis that the appearance of the 
mammalian brain with the ability to acquire drives produced species with manipulability to 
fit for domestic life, i.e. to life in intimate association with and to the advantage of humans. 
To study the nature of the acquired drives, a special model was developed, the training of 
rats in a way that they fix in their cortex an unnatural urge, the so-called glass-cylinder-
seeking drive. Those rats that performed best acquired this drive in a stable manner and 
maintained this unnatural urge for a life time. Knoll summarized the results and described 
the conclusion of his first 16-year research period with the glass-cylinder-seeking rats in a 
monograph (Knoll, 1969) and finally presented, after a further 36-year research period, his 
theory “The Brain and Its Self. A Neurochemical Concept of the Innate and Acquired 
Drives” in a second monograph (Knoll, 2005). His theory, based on the physiology of the 
acquired drives, furnishes knowledge about the most important brain mechanisms which 
created the society: the manipulability of the cortex.  
An acquired drive is always built on an inner drive, however, after the acquired drive has 
been ultimately fixed, its origin, the innate drive, cannot be recognized anymore either in 
man or a domesticated animal. A glass-cylinder-seeking rat will never acquire this drive 
under natural conditions. The experimenter manipulated consciously its brain, making use 
of the innate potential to change a group of cortical neurons via proper training in a way 
that the rat is fixing an acquired drive. In case of a fully successful training, the glass-
cylinder-seeking rat behaves as one who has a fanatical desire for the glass-cylinder. These 
rats showed the same high-grade adaptability and readiness in overcoming different 
obstacles during goal-attainment as the ones influenced by innate drives, such as hunger or 
sexual desire. “Humans possess the most manipulable brain among all living creatures on 
earth. The brain of a suicide-killer is furtively manipulated. The properly acquired drive 
develops as a result of long-lasting training. The subject always acts under coercion, under 
severe mental pressure. Nevertheless, it is the nature of acquired drives that if the 
manipulation was fully successful the individual ultimately behaves as one possessing a 
fanatical desire to reach the acquired-drive-motivated goal.” (Knoll, 2005, p 139).  
It was at the beginning of these behavioral studies that the need for a new type central 
stimulant, a proper experimental tool for studying the physiology of the acquired drives, 
emerged. Knoll’s aim was to find an amphetamine-like psychic energizer without the side-
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effect of the amphetamines that as soon as the dose is surpassing the 1-2 mg/kg level, the 
drug-induced continuous, irresistible release of catecholamines from their intraneuronal 
stores in the brain stem neurons arrives to an intensity resulting in aimless hypermotility 
which blocks purposeful behavior. Since in those times the MAO inhibitors represented a 
new type of central stimulants, he decided to approach his goal via a structure-activity-
relationship study, the starting structure of which was methamphetamine, containing, in 
order to make the molecule capable to block MAO activity irreversibly, a propargyl-group 
attached to the nitrogen.  
Out of a series of newly synthesized patentable propargyl-group-containing 
methamphetamine-derivatives Knoll selected finally E-250 for further development. 
Amphetamines, the synthetic long acting analogues of PEA are like their parent compound 
releasers of noradrenaline from their intraneuronal stores, thus they increase blood pressure. 
E-250 behaved anomalously. It did not increase blood pressure; it even inhibited the blood 
pressure increasing effect of its parent compound (see Knoll et al., 1965, Fig.1). Knoll 
realized the peculiar practical importance of this behavior and demonstrated that this 
compound, in contrast to all known MAO inhibitors, does not potentiate, but inhibits the 
effect of tyramine, thus it is free of the cheese effect (Knoll et al., 1968). This feature of D 
allowed later to combine it safely with levodopa in PD and initiated its world-wide use as a 
therapeutic agent (Birkmayer et al., 1977).  
3. The period while the selective inhibition of MAO-B in the brain was thought 
to be fully responsible for the therapeutic effects of deprenyl 
In the same year when Knoll demonstrated with two of his coworkers that D is free of the 
cheese-effect (Knoll et al., 1968), Johnston described a new irreversible MAO inhibitor, MB 
9302 (later named clorgyline), which preferentially inhibited the deamination of serotonin 
(Johnston, 1968). Johnston proposed the existence of two forms of MAO, “type A” and “type 
B”, the former being selectively inhibited by clorgyline and the latter insensitive to it. This 
nomenclature has become widely accepted and is still in use. The unique substrate 
specificity of this new MAO inhibitor was soon corroborated (Hall et al., 1969), and 
clorgyline became the classic experimental tool to inhibit selectively MAO-A.  
In MAO research a selective inhibitor of MAO-B was badly needed and Knoll realized that 
D was the missing link, the highly selective inhibitor of MAO-B. He presented this finding 
first in 1971 in his lecture at the first international MAO meeting in Cagliari (Sardinia). D 
was used thereafter as the specific experimental tool to analyze MAO-B. The first paper 
which described this novel property of D (Knoll  Magyar, 1972) became 10 years later a 
citation classic (Knoll J., This Week’s Citation Classic, January 15, 1982). After the discovery 
that D is a selective inhibitor of MAO-B this property of the compound remained for years 
in the center of his interest. He pointed for the first time in his lecture at the second 
international MAO meeting “Monoamine Oxidase and its Inhibition” organized by the 
CIBA Foundation in London 1975, to the importance to study carefully the consequence of 
the relation between PEA and D.  
Since PEA, the physiologically important endogenous central nervous system stimulant is a 
specific substrate for MAO-B, thus D is increasing exceedingly PEA levels in the brain, he 
mentioned in the summary of this lecture that D in combination with PEA might be efficient 
in certain types of depression. In the discussion of his lecture (Knoll, 1976, pp 155-160) he 
referred repeatedly to the importance of this line of further research. A couple of years later, 
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following Knoll’s proposal, the antidepressive efficacy of D (5-10 mg daily) plus 
phenylalanine (250 mg/day), the precursor of  PEA, has been evaluated in 155 unipolar 
depressed patients. Both oral and intravenous administration of the combination showed 
beneficial effect in 90% of outpatients and 80.5% of inpatients. It was concluded that this 
combined treatment has a potent antidepressive action based on the accumulation of PEA in 
the brain (Birkmayer et al., 1984).   
In a further study Knoll enlarged his concept that D offers a previously unknown possibility 
to exploit the natural endowments of PEA and argued as follows (see Knoll, 1978a, 
p.59):”…a progressive significant decrease in the dopamine content of the nigrostriatum is 
to be observed at the decline of life….The physiological decrease of the dopamine content of 
the striatum could easily be prevented by the continuous administration of a small dose of  
(-)-deprenyl….”, moreover: “There is now ample evidence that phenylethylamine is 
endogenous in the brain and might play a role in affective behavior. Urinary excretion of 
free phenylethylamine was found to be reduced in depressed patients supporting the 
hypothesis that phenylethylamine deficit may be one of the biochemical lesions in 
depression…”.  
In the same year, in another lecture (Knoll, 1978b) he emphasized the importance to begin 
the administration of D in the earliest state of parkinsonism. The validity of Knoll’s proposal 
to begin the administration of this drug in the earliest state of PD got splendid verification a 
decade later in the Deprenyl and Tocopherol Antioxidant Therapy of Parkinsonism 
(DATATOP) study performed on selected patients with early untreated PD. It was shown 
that the administration of D delays significantly the onset of disability necessitating 
levodopa therapy (Tetrud  Langston, 1989; Parkinson Study Group, 1989). Knoll’s close 
reasoning in this time was as follows: “Considering the mechanism of action of (-)-deprenyl 
it seems to be of high importance to begin the administration of this drug in the earliest state 
of parkinsonism, in order to preserve as far as possible the physiological control of 
acetylcholine release in the striatum thereby reducing the amount of the required levodopa 
to the lowest possible level. Even the known slow degradation of the nigrostriatal 
dopaminergic neurons, a frequent phenomenon of ageing, might be counteracted by starting 
long term treatment with low doses of (-)-deprenyl in due time.” (Knoll, 1978b, p 195). 
Furthermore, it is evident from the discussion quoted from this study that the concept to 
slow the physiological age-related decline of the dopaminergic machinery in the brain stem 
via prophylactic low dose D treatment, took slowly its final shape, and we may say in 
retrospect that Knoll’s coming important longevity studies (Knoll, 1988; Knoll et al., 1989, 
1994) cast in this paper their shadows before. 
We can also follow in these years Knoll’s method that whenever he wanted to prove 
undeniably the relevance of a well defined pharmacological effect of D in its therapeutic 
efficiency he started a structure-activity-relationship study and fabricated a D-derivative 
which differed only in its pharmacological spectrum from its parent compound in being 
devoid of the questionable property. For example, he found that D is a potent inhibitor of 
the uptake of amines into the nerve endings of catecholaminergic neurons.  
Since he wanted to test the significance of the monoamine-uptake inhibitory property of D 
in its therapeutic effect, he developed selective MAO-B inhibitors, J-508 and U-1424, devoid 
of this effect (Knoll et al., 1978c). Using N-methyl-N-propargyl-/l-indenyl/-ammonium  
(J-508) as a reference compound which acts as a highly potent MAO inhibitor, devoid of 
uptake-inhibitory and releasing effects, the influence of MAO inhibitors on uptake was 
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tested on a battery of isolated organs (cat nictitating membrane, perfused ear artery and 
strip of pulmonal artery of the rabbit, rat vas deferens).  
In contrast to the nonselective and A-selective MAO inhibitors, as well as to the newly 
introduced selective MAO-B inhibitors (J-508, U-1424), D was unique in inhibiting tyramine-
uptake. This means that D is unique in being free of the cheese effect. This was for example 
the reason why Knoll did not suggest developing J-508 as a therapeutic agent, despite that 
this compound was found to be a 20-times more potent selective inhibitor of MAO-B than D 
(Knoll, 1978c, Table 2).  
It is remarkable in this context that, about 30 years later, the desmethyl-analogue of J-508 
(Rasagiline) was registered as a “new” second generation selective MAO-B inhibitor with 
the argument that since (-)-methamphetamine is a metabolite of D of which rasagiline is 
free, this is the advantage of rasagiline over D. Everybody who reads the literature knows 
that this is a sham-argument in support of a “me too” compound. An exact experimental 
study (Yasar et al. 1993) proved that D is free of amphetamine-like dependence capacity, 
they concluded:”…the preclinical findings reviewed generally support the clinical 
experience that in over 20 years of therapeutic use there has been no established case of 
human abuse l-deprenyl.” (Yasar et al., 1993, p 230).  Furthermore, it is absolutely out of the 
common that there is nowhere the slightest hint in the rapidly increasing rasagiline 
literature that since this compound is the desmethyl-analogue of J-508, the pharmacology of 
which was described in detail 30 years ago, the developers carefully compared the 
pharmacological spectrum of rasagiline and J-508 showing its advantage over its parent 
compound. Since J-508 is devoid of the catecholaminergic activity enhancer (CAE) effect 
characteristic to D, we tested in this respect rasagiline in the shuttle box and found that this 
J-508 analogue bears resemblance to its parent compound and not to D (Miklya, 2008).  
Influenced by new experimental data Knoll became suspicious that an unknown stimulatory 
effect and not MAO-B inhibition might primarily be responsible for the therapeutic benefits 
of the drug. By changing the propargyl moiety, which binds covalently with the flavin in 
MAO, to a propyl group, he developed 1-phenyl-2-propylamino-pentane (PPAP), a D-
analogue, free of MAO-B inhibitory potency (Knoll et al., 1992a). He described in his 
monograph (Knoll, 2005) the essence of the PPAP story as follows: “With the development 
of (-)-1-phenyl-2-propylaminopentane, (-)-PPAP, the (-)-deprenyl analogue free of the MAO-
B inhibitory potency, we already furnished direct evidence that the enhanced dopaminergic 
activity following administration of (-)-deprenyl was unrelated to the inhibition of MAO-B. 
Because (-)-PPAP, like (-)-deprenyl, inhibited the uptake of tyramine in isolated smooth 
muscle tests, we first assumed that the drug-induced enhanced dopaminergic activity was 
due to an uptake inhibitory effect. Further studies revealed that this interpretation was 
false.” The discovery of the CAE effect in the early 1990s clarified the main mechanism 
through which D is enhancing the activity of the nigrostriatal dopaminergic neurons and 
terminated the period when the selective inhibition of MAO-B was in the center of interest. 
4. Longevity studies. The proof that lifelong administration of deprenyl slows 
significantly the age-related decline of sexual performance and learning 
ability and prolongs life 
The first paper which furnished experimental evidence for the pressing necessity to start a 
longevity study is the one entitled “Can the suicide inactivation of MAO by deprenyl 
explain its pharmacological effects?” (Knoll, 1981a). In this paper the pharmacological 
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spectrum of D was reviewed and experimental and clinical evidence was listed proving that 
D facilitates via different mechanisms the dopaminergic modulation in the brain. The 
putative physiological role of extrasynaptosomal MAO, which is of the B-type, in the 
dopaminergic and “trace aminergic” modulation and its significance in the therapeutic 
effect of D was analyzed. The working hypothesis was proposed that the age-related 
increase in MAO-B activity in the human brain is the biochemical lesion in senescence which 
results in a decline of dopaminergic and “trace aminergic” modulation and triggers many of 
the phenomena (slight parkinsonian syndrome, anxiety, depressed mood, severely inhibited 
sexual performance, etc.) known to accompany the aging process. The obvious possibility to 
prevent or counteract the MAO-B related consequences of aging by long-term treatment 
with D was discussed. It was shown in this paper first that D is significantly improving the 
sexual performance of sluggish male rats and clorgyline is devoid of this property. The 
aphrodisiac effect of D in aged sluggish male rats was further demonstrated in a couple of 
papers (Knoll, 1981b; Yen et al., 1982; Knoll et al., 1983).  
Knoll presented his fully elaborated strategy to improve the quality of life in senescence via 
the prophylactic life-long administration of D in his lecture delivered at the “Strategy of 
Drug Research” IUPAC-IUPHAR Symposium in Nordwijkerhout (The Netherlands) in 
1981. He summarized his views as follows: “In the aging brain, there is a loss of neurons 
compensated for by a proliferation of glial cells. We might thus predict that dopaminergic 
and “trace aminergic” modulation in the brain declines in senescence because of loss of 
neurons and because of the increased monoamine oxidase (MAO)-B activity present in the 
glia. The hypothesis was forwarded that the significant increase of the incidence of 
depression in the elderly, the age-dependent decline in male sexual vigor and the frequent 
appearance of parkinsonian symptoms in the latter decades of life might be attributed to a 
decrease of dopamine and “trace amines” in the brain. The possibility to counteract these 
biochemical lesions of aging by chronic administration of (-)-deprenyl, a selective inhibitor 
of MAO-B, which facilitates dopaminergic and “trace aminergic” activity in the brain and is 
a safe drug in man, was analyzed in detail. The restitution and long term maintenance of full 
scale sexual activity in aged male rats continuously treated with (-)-deprenyl was 
demonstrated as an experimental model in support of the view that the long term 
administration of small doses of deprenyl may improve the quality of life in senescence” 
(Knoll, 1982, p 107).   
In one of his following studies “Deprenyl (selegiline): the history of its development and 
pharmacological action” (Knoll, 1983), he reviewed experimental and clinical data to show 
the potential benefits of using D in the elderly. He referred for example to a paper which 
showed that D significantly prolonged the duration of PD, i.e. the lifespan of the D-treated 
patients was substantially extended (Birkmayer, Knoll et al., 1983). Knoll’s hypothesis 
inspired this clinical analysis and led later to a more extensive analysis of Birkmayer’s 
clinical data which definitely showed increased life expectancy resulting from addition of D 
to Madopar-treatment in PD (Birkmayer, Knoll et al., 1985).  
In 1983 Knoll introduced his concept regarding the peculiar antiaging effect of D to the 
gerontologists in a lecture presented at the 7th European Symposium on Basic Research in 
Gerontology (Budapest, Hungary). He presented in this lecture new data to demonstrate 
that since the dopaminergic system represents the most rapidly aging neuronal network in 
the human brain, we lose after age 45 about 13% of our dopamine per decade, and D 
facilitates without side effects in a unique manner dopaminergic activity, which plays a 
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leading role in the age-related decline of learning ability and sexual potency, it is reasonable 
to try to improve the quality of life in senescence via the prophylactic life-long small-dose 
administration of D (Knoll, 1985).  
Knoll performed on a special, long-living strain of rats (first generation Wistar males x 
Logan females), with his two coworkers, Dallo and Yen, his first longevity study between 
1984 and 1988. The concept and teaching of this study was published in a crucially 
important paper (Knoll, 1988) and in a brief summary (Knoll et al., 1989).  
The study revealed that better performers in the mating test are better learners in the shuttle 
box and the more active animals live significantly longer than their less active peers. It was 
established by the aid of D which increased superoxide dismutase activity in the striatum, 
facilitated the activity of the nigrostriatal dopaminergic neurons with utmost selectivity, and 
protected these neurons from their age-related decay, that the efficiency of a rat in 
behavioral test, as well as the duration of its life are striatal dopamine dependent functions.  
As a measure of striatal function, sexual activity was tested once a week in a group of male 
rats (n=132) from 24th month of their life. Because of the age-related decay of this function 
none of the 2-year-old animals displayed full scale sexual activity. By dividing the group 
equally the rats were treated with saline and D (0.25 mg/kg sc.), respectively, three times a 
week. In the saline-treated group (n=66) the last signs of sexual activity vanished to the 33rd 
week of treatment. D-treatment restored full scale sexual activity in 64 out of 66 rats. The 
longest living rat in the saline-treated group lived 164 weeks. The average lifespan of the 
group was 147.050.56 weeks. The shortest living animal in the D-treated group lived 171 
weeks and the longest living rat died during the 226th week of its life. The average lifespan 
was 197.982.36 weeks, i.e. higher than the estimated maximum age of death in the rat (182 
weeks). This was the first instance that by the aid of a well-aimed medication, members of a 
species lived beyond the known lifespan maximum. Further detailed studies in Knoll’s 
laboratory corroborated the results of the first longevity study. It was demonstrated that rats 
treated during their post-developmental phase of life with a small dose of D lost their ability 
to ejaculate later (Knoll et al., 1989; Knoll, 1992; Knoll et al., 1994), showed a slower decline 
in learning performance with the passing of time (Knoll, 1989; Knoll et al., 1989, 1994), and 
lived significantly longer than their saline-treated peers (Knoll et al., 1989, 1994).  
The original finding that D prolongs life was confirmed in rats (Milgram et al., 1990; Kitani 
et al., 1993), mice (Yen  Knoll, 1992; Freisleben et al., 1994; Archer et al., 1996), hamsters 
(Stoll et al., 1997), and dogs (Ruehl et al., 1997). In one strain of mice D-treatment had no 
beneficial effect on survival (Ingram et al., 1993); and Stoll et al. (1997) found increased 
lifespan in D-treated female hamsters only. Moreover, in the longevity studies substantial 
strain differences were found in the efficiency of D. It has to be considered, however, that 
enhancer substances stimulate the enhancer-sensitive neurons in the brain stem in a peculiar 
manner. Thus, the same dose of an enhancer drug may exert a peak effect on one strain, a 
much lower effect on an other strain, and be ineffective on a third strain (see Main Heading 
5 for details).  
One group found, in striking contrast with all other studies, an increased mortality in male 
Wistar rats treated with D 0.5 mg/kg for up to 20 months (Gallagher et al., 1998). The 
toxicological studies performed with D and decades of experiences on thousands of rats 
make clear that the administration of D 0.5 mg/kg 3 times a week could not be responsible 
for the observed increased mortality in the rats. It is worth mentioning that even in clinical 
studies improper combination of levodopa with D led to confusion and misinterpretation as 
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it happened in a study performed by the Parkinson’s Disease Research Group of the United 
Kingdom and published in 1995 (Lees, 1995; for a critical analysis see Knoll, 1998).    
5. The catecholaminergic activity enhancer (CAE) effect of deprenyl 
The availability of HPLC to measure exactly the catecholamines and serotonin in 
physiological quantities allowed a new approach. The thorough analysis of the dose-
dependent effect of D on the release of catecholamines and serotonin from isolated, discrete, 
rat brain regions (dopamine from the striatum, substantia nigra and tuberculum 
olfactorium; noradrenaline from the locus coeruleus; and serotonin from the raphe) pointed 
to operation of a previously unknown peculiar enhancer regulation in the catecholaminergic 
neurons in the brain stem. 
Rats were treated with 0.01, 0.025, 0.05, 0.1 and 0.25 mg/kg D, respectively, once daily for 21 
days. Discrete rat brain regions were isolated 24 hours after the last injection and the 
biogenic amines released during 20 min from the freshly isolated tissue samples were 
measured. The amount of dopamine released from the substantia nigra and tuberculum 
olfactorium clarified that the dopaminergic neurons worked on a significantly higher 
activity level even in rats treated with the lowest, 0.01 mg/kg dose of D. As this small dose 
of D leaves the MAO-B activity and the uptake of amines practically unchanged, this study 
was the first unequivocal demonstration for the operation of a hitherto unknown enhancer 
mechanism in dopaminergic neurons stimulated by D in very low doses (Knoll  Miklya, 
1994). D enhanced also the release of noradrenaline from the locus coeruleus, but did not 
enhance, even diminished the release of serotonin from the raphe. Thus, D proved to exert a 
highly specific, previously undetected CAE effect. 
Further studies revealed that the parent compounds of D, PEA and methamphetamine, are 
primarily CAE substances but this property remained undetected because PEA and its long 
acting derivatives, amphetamine and methamphetamine, induce the continuous release of 
catecholaminergic transmitters from their neuronal pool which hinders completely the 
detectability of the CAE effect of these compounds. Since D is the only PEA-derived CAE-
substance which is devoid of the catecholamine releasing property, it enabled to discover the 
enhancer regulation in the catecholaminergic neurons of the brain stem (Knoll et al., 1996a,b). 
An additional proof of the operation of the enhancer regulation in the brain stem was the 
discovery that tryptamine is a natural enhancer substance which acts primarily on the 
serotonergic neurons (Knoll, 1994, for review see Knoll, 2005, 3.1.1). This experience 
catalyzed later the structure-activity-relationship study aiming to develop a tryptamine-
derived enhancer substance and led finally to the selection of R-(-)-1-(benzofuran-2-yl)-2-
propylaminopentane (BPAP),  which is in rat experiments about hundred times more potent 
than D, for further development (Knoll et al., 1999). In contrast to D which is almost 
ineffective on the serotonergic neurons, BPAP is a highly potent enhancer of the 
serotonergic neurons.  
Fig.1 and 2a,b show the striking difference between the catecholamine-releasing and the 
CAE effect. 
The enhancer substances stimulate the enhancer sensitive neurons in the brain stem in a 
peculiar manner. Fig.3 shows, as an example, the bi-modal, bell-shaped concentration curve 
characteristic to the enhancer effect of BPAP, the presently known most potent and selective 
enhancer substance.  The one in the low nanomolar range, with a peak effect at 10-13M 
concentration, clearly demonstrates the existence of a highly complex, specific form of 
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enhancer regulation in noradrenergic neurons. The second, with a peak effect at 10-6M 
concentration, shows the operation of a ten million times less sensitive, obviously 
nonspecific form of the enhancer regulation in these neurons (Knoll et al., 2002).  
6. Deprenyl-induced enhancement of scavenger function in the striatum 
Knoll brought up for the first time in 1987 his idea that D may facilitate scavenger function 
in striatal neurons (Knoll, 1987). In a section of this paper, entitled “The putative role of 
scavenger function changes in the long-term deprenyl treatment induced protection of the 
nigrostriatal dopaminergic neuron”, he referred to their experiences that the physiological 
consequences of the dopaminergic regulation in the caudate nucleus are detectable by 
measuring the basal ouabain-stimulated release of acetylcholine (ACh) (Knoll, 1978c).  
Dopamine cell bodies dominating in the A9 and A10 of the substantia nigra produce such 
large amounts of dopamine that the striatum, in which neurons terminate, contains the 
highest amount of dopamine in the brain. The physiological role of dopamine released in 
the striatum is the continuous inhibition of the release of ACh from the cholinergic 
interneurons of the caudate nucleus.  According to data shown in this paper (Knoll, 1987, 
Table 6) the amount of ouabain-induced release of ACh from isolated striatal slices dissected 
from untreated rats was found to be 366.757.3 pmole/g/min and the addition of dopamine 
(2.6 x 10-4 mole/L) increased the amount to 591.052.5 pmole/g/min, showing that 
dopamine stimulated the presynaptic dopamine “autoreceptors”. In striatal slices taken 
from rats pretreated with 6-hydroxydopamine (6-OHDA) the ouabain-induced release of 
ACh increased to 706.060.0 pmole/g/min, similarly to the situation in PD, where loss of 
the nigrostriatal dopaminergic neurons leads to an uninhibited release of ACh in the  
 
 
Fig. 1. Demonstration that amphetamine, the synthetic PEA-derivative, is inducing a long 
lasting spontaneous release of 3[H]-noradrenaline from an isolated rat brain stem and 
electrical stimulation is ineffective, showing that the detectability of the enhancer effect is 
hindered.  
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striatum. The addition of dopamine inhibited to 372.993.8 pmole/g/min the ouabain-
induced release of ACh, thus acted in the model like levodopa acts in PD.  
 
 
(a) 
 
 
(b) 
Fig. 2. a. Release of 3[H]-noradrenaline from an isolated rat brain stem to consecutive 
electrical stimulations. There is a slow decline in response due to the exhaustion of the 
isolated organ. b The demonstration that since D is devoid of the spontaneous releasing 
effect of 3[H]-noradrenaline characteristic to amphetamines, the CAE effect of D, the 
powerful enhancement of the release of 3[H]-noradrenaline to electrical stimulation, is 
detectable.  
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Fig. 3. The concentration effect curve characteristic to the CAE effect of enhancer substances. 
(The enhancer effect of BPAP on isolated locus coeruleus of rats is shown. For details see 
Knoll et al., 2002.); *p0.01, **p0.001. 
D-treatment protected completely the striatum from the toxic effect of 6-OHDA. The s.c. 
injection of 0.25 mg/kg D for 3 weeks and the administration of 6-OHDA 24 hours after the 
last injection of D did not change the ouabain-induced release of ACh. Regarding the 
mechanism of this protection, Knoll concluded: “…the blockade of B-type MAO, the 
inhibition of the uptake of 6-OHDA into the neuron and the facilitation of scavenger 
function, the improvement of the removal of the neurotoxic free radicals may have shares in 
the highly efficient shielding effect of (-)-deprenyl” (Knoll, 1987, p 57). It was shown later 
that D increases dopamine transporter (DAT) expression but the new DAT molecules 
appear not to be functionally active (Lamensdorf et al., 1999). 
After this conclusion, it was a reasonable step forward to test the effect of D on the 
scavenger mechanism in the striatum. And we really find in Knoll’s next paper the first data 
showing that daily administration of D for three weeks is significantly enhancing the 
activity of superoxide dismutase (SOD) in the striatum of both male and female rats (Knoll, 
1988, Table VII). This was an important discovery. The finding was soon confirmed by 
Carrillo et al. who found that also catalase activity was induced by D (Carrillo et al., 1991).  
Knoll showed that D has no direct effect on brain SOD activity in general. Using the 
cerebellum as a reference tissue, he showed that SOD activity in this area did not change in a 
statistically significant manner in D-treated male and female rats (Knoll, 1989).  Carrillo et al. 
confirmed also this finding. They showed in rats that activities of both SOD and catalase 
were significantly increased in striatum and substantia nigra but not in hippocampus, 
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cerebellum and liver (Carrillo et al., 1992a). They also demonstrated that in old male mice D 
increased SOD and catalase activities in the substantia nigra, striatum and cerebral cortex, 
but not in hippocampus, cerebellum or liver (Carrillo et al., 1994a). Furthermore, in 
accordance with the finding in rats, D increased SOD activity in the striatum, but not in the 
hippocampus of beagle dogs (Carrillo et al., 1994b). Knoll demonstrated that D-induced 
enhancement of the SOD activity in the striatum of CFY rats was unrelated to the MAO 
inhibitory effect of the drug. Clorgyline, one of the most potent MAO inhibitors, inhibited 
rather than enhanced striatal SOD activity in rats (Knoll, 1988, 1990).  
As we discussed earlier, the peculiar dose-dependency of the CAE effect of the enhancer 
substances (see Fig.3) clearly indicates the need of special caution regarding the optimal 
dosage with respect to each effect of D and other enhancer substances. Regarding the 
scavenger function of D, Carrillo et al. studied in detail the sex and age-dependency on the 
optimal dosage of this effect in rats (Carrillo et al., 1992b, 1993). The perplexed problem of 
the optimal dosage of D for increasing lifespan was analyzed and discussed between 1994 
(Carrillo et al., 1994c) and 2006 (Kitani et.al., 2006) in a dozen of papers. 
7. Neuroprotective effect of deprenyl 
Hundreds of experimental studies prove that D protects against a couple of toxins (MPTP, 6-
OHDA, DSP-4, AF64-A) and is a highly potent neuroprotective agent. The first study showing 
that D reduces PC12 cell apoptosis by inducing new protein synthesis was published by 
Tatton et al. (1994). Since this effect was exerted in concentrations as low as  
10-13M it was clear that the neuroprotective effect of D is unrelated to MAO-B inhibition 
(Tatton, et al. 1996). The real unanswered question is the mechanism through which D is 
protecting so many different cells against diverse deleterious effects. Knoll’s arguments in 
support of the assumption that the CAE effect of D might be primarily responsible for most of 
the beneficial therapeutic effects of the drug (Knoll, 1998) require much thought. As a matter of 
fact, Tatton’s finding was already prima-facie experimental evidence supporting Knoll’s 
concept. D reduced PC12 cell apoptosis in 10-13M concentration, exactly in the range where D 
exerts its CAE effect. The final proof, however, of the key importance of the enhancer effect in 
the neuroprotective capacity of the enhancer substances was the development of   (-)-BPAP, a 
more potent enhancer substance than D which has no chemical similarity to the 
propargylamines. In the first paper which described the pharmacological profile of this new 
experimental tool, the relation of the neuroprotective property of this compound to its 
enhancer effect was demonstrated (Knoll et al., 1999). In this study the protective effect of 
racemic BPAP was measured against -amyloid induced neurotoxicity on cultured rat 
hippocampal neurons, showing that enhancer substances might favorable influence AD. 
At the 10th day the cultured cells were injured by exposing them for 3 days to a 20 µM 
concentration of -amyloid 25-35 fragment. This concentration of -amyloid decreased the 
survival of the neurons (control=100%) to 22.4±7.20% (mean±S.D.). BPAP significantly 
inhibited the -amyloid induced neurotoxicity in the cultured hippocampal neurons in two 
distinct ranges of concentration, one with a peak of 10-14M and one with a peak of 10-8M. The 
peculiar concentration dependency of the effect of BPAP on the hippocampal neurons was 
surprisingly identical with that on the noradrenergic neurons, showing that the cell device 
in service of the enhancer regulation might be very similar to each other in the different 
enhancer-sensitive neurons (see Knoll 2001, Fig 13 and 14). 
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The interpretation of the finding in the first paper describing the pharmacology of (-)-BPAP 
(Knoll et al., 1999, p 1731) needs still serious consideration: “As a matter of fact there is a 
conspicuous similarity between the BPAP induced effect on the cultured rat hippocampal 
neurons and the one induced by (-)deprenyl in rats treated with the drug for years during 
their post-developmental phase of life. In the (-)deprenyl experiment we picked out of a 
population of 1600 rats the animals with the lowest and the highest sexual performance and 
demonstrated, on the one hand, that the ‘high performing’ rats lived significantly longer 
than their ‘low performing’ peers, and on the other hand, that (-)deprenyl treatment 
transformed the low performing rats into significantly higher performing ones, which lived 
then as long as their saline treated high performing peers (Knoll et al., 1994). We assume 
that high performing, longer living rats possess a more efficient catecholaminergic brain 
machinery than their low performing peers and the treatment with (-)deprenyl, a CAE 
substance, acts accordingly. Whatever performance we measure in a random population, we 
always find a huge variation in efficiency, ranging from very low to very high performing 
individuals. This is true also regarding the performance of cells in a population of cultured 
neurons. We may look at the 20% of the cultured hippocampal neurons which survived in 
the presence of -amyloid, as ‘high performing’ cells, those possessing the most efficient 
BPAP-sensitive activation mechanism. Adding to the cultured neurons BPAP in the 
optimum concentration (10-14M), the highly potent and selective enhancer of this regulation 
made each neuron higher performing and the surviving rate increased from 20% to 70%.  
BPAP has obviously the same effect on the noradrenergic, dopaminergic, serotoninergic and 
hippocampal neurons. It may stimulate endogenous substances which enhance the activity 
of the neurons according to their physiological need. The high potency of BPAP in 
stimulating this regulation makes search in the brain after much more potent endogenous 
‘enhancer’ substances than PEA and tryptamine, reasonable”.  
Hundreds of papers were published on the diverse effects of D, among them unexpected 
ones, like for example antitumor effect (ThyagaRajan  Felten, 2002), peculiar influence on 
stem cells (Esmaeili et al., 2006), enhancement of the secretion of the neurotrophic factors 
(Ohta et al., 2002; Shimazu et al., 2003), etc. It is the most important to decide which effect of 
the drug is primarily responsible for the verified benefits in PD, AD, major depression, and 
for its antiaging effect.  Since the CAE effect of D is still not common knowledge, authors 
may remain inattentive to their findings which give clear information about this mechanism.  
An example: Groc et al. (2000) presented evidence of D insensitive apoptosis of nigral 
neurons during development. They found that apoptotic death of dopamine neurons during 
development is insensitive to daily treatment of the pregnant mothers and then newborns 
with D 0.1, 1.0, or 10 mg/kg. This finding informs about the key importance of the enhancer 
regulation in the effectiveness of D. Since the enhancer regulation in the brain of rats starts 
working only at the discontinuation of breast feeding (end of the third week of age) (Knoll  
Miklya, 1995),it is obvious that apoptotic death of nigral neurons is insensitive to daily 
treatment of D before that age.  
A second example: Ohta et al. (2002) studied the effects of BPAP, the newly developed 
enhancer substance, on cultured mouse astrocytes, measuring one of their specific functions 
the secretion of neurotrophins. They found that astrocytes treated for 24 hours with 0.35mM 
BPAP secreted into the culture medium 120, 2 and 7 times more NGF, BDNF and GDNF, 
respectively, than the untreated (control) cells. As Fig.3 demonstrates, BPAP exerts a specific 
enhancer effect in picomolar concentrations and a nonspecific one in micromolar 
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concentration. Since Ohta et al. investigated the effect of BPAP in high concentration only 
and because it is well-known that neuroglial cells play an important physiological role in the 
brain and modulate the function of neurons in a complex manner, but do not participate in 
the modification of behavioral functions, whereas BPAP is in the low pico/nanomolar 
concentration range influencing behavior, Knoll performed with coworkers a second study, 
testing BPAP on cultured mouse astrocytes in a range of 10-15M to 5x10-4M concentration. 
This study corroborated the finding of the first one. The synthesis of NGF was significantly 
enhanced in the high micromolar concentration range with a peak effect at 10-4M 
concentration, whereas 5x10-4M was ineffective. BPAP acted similarly on the synthesis of 
BDNF and GDNF. But the crucial step forward was the proof that, as expected, BPAP was 
ineffective in the low concentration range. Thus the specific form of enhancer regulation was 
not detectable in glial cells (Shimazu et al., 2003).  
It can be little doubt that to differentiate between the specific and nonspecific enhancer 
effect of D requires consideration. Nevertheless, it remains for the future to identify the 
specific macromolecular target(s) that accommodate the endogenous enhancer substances 
and their synthetic derivatives; to demonstrate the existence of the predicted endogenous 
enhancer substances that are much more potent than PEA or tryptamine; and to map the 
enhancer-sensitive neurons and other cells in the brain, even if we know that the neurons of 
the catecholaminergic and serotonergic systems in the brain are probably the 
physiologically, biochemically, and pharmacologically best studied constituents of the CNS.  
For the time being it is unpredictable how many enhancer sensitive-cells exist the activity of 
which can be influenced by enhancer substances. An example: Denes et al. (2006) 
demonstrated that like the widely investigated rat PC12 cells, also human brain capillary 
endothelial cells (HBEC) are enhancer sensitive ones. Both D and BPAP exerted their 
significant cytoprotective effect on both HBEC and rat PC12 cells with the dose-dependency 
characteristic to the enhancer substances.  
8. The rational of Knoll’s concept that prophylactic deprenyl therapy may 
decrease the prevalence of neurodegenerative diseases, like Parkinson’s and 
Alzheimer’s 
The dopaminergic system the neurons of which originate in the substantia nigra pars 
compacta, ventral tegmental area and hypothalamus is influencing many important brain 
functions playing a key role in the ability of the human brain to acquire new behavior. 
According to present knowledge the nigrostriatal dopaminergic neurons are the most 
rapidly aging neurons in the human brain. The dopamine content of the human caudate 
nucleus decreases steeply, at a rate of 13-15% per decade over age 45. We know that 
symptoms of PD appear if the dopamine content of the caudate sinks below 30% of the 
normal level. Aging of the nigrostriatal dopaminergic neurons is essentially similar in 
rodents and in humans. Direct biochemical evidence for the age-related decline of the 
dopaminergic function in rat is the loss of striatal D2-receptors in the aging brain.  
Dopamine itself might play a main role in the unusually drastic age-related changes of the 
nigral dopaminergic system. 80% of brain dopamine is localized here. The complex 
autooxidation of the large amounts of DOPA and dopamine in the striatum continuously 
generating substantial quantities of toxic free radicals and highly reactive quinones, creates 
a permanent danger for the nigrostriatal dopaminergic neuron, which has to mobilize its 
natural defensive measures against these toxic metabolites. Neuromelanin, which is 
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synthesized via the polymerization of oxidative products of dopamine, with the evident aim 
of finally depositing waste products, is in the substantia nigra the visible sign of successful 
self defense of the neuron against the free radicals and quinones originating from dopamine 
metabolism. The sluggish depositing of neuromelanin in the human substantia nigra is in 
excellent agreement with this view.   
Knoll and his coworkers found that small dose D treatment prevented in rats age-related 
morphological changes in the neurons of the substantia nigra (Knoll et al., 1992b). This 
experimental study was in harmony with the clinical experience of Rinne et al. (1991) who 
found that the number of medial nigral neurons was greater and the number of Lewy bodies 
fewer in those PD patients who had been treated with D in combination with levodopa 
when compared with patients who had received levodopa alone. Collating the human data 
with the results of Knoll et al.’s study in rats it is reasonable to assume that D-treatment 
retards the death of the nigral neurons in the patients.  
It is evident that if we focus our attention in our fight against the manifestation of PD via 
protecting the age-related decay of the dopaminergic machinery in the brain, we must not 
forget that the prophylactic low dose administration of D is strongly enhancing also the 
noradrenergic neurons. D and BPAP are highly potent stimulants of the noradrenergic 
system (Knoll, 2005). Fig.3 shows as an example that BPAP is enhancing the release of 3[H]-
noradrenaline from the isolated locus coeruleus in picomolar concentration and D acts 
similarly (see Fig.2b). Thus, it is of significant importance to follow those experimental and 
clinical studies which call attention to an inverse relationship between brain noradrenaline 
level and dopamine loss in PD (Tong et al., 2006). Zarow et al. (2003) showed in a study that 
in AD and PD neuronal loss in the locus coeruleus is greater than in substantia nigra. Locus 
coeruleus is a neuromelanin-pigmented neuronal structure (Ararat et al., 1977) and it is 
known that in PD and AD morphological alterations of the noradrenergic neurons result in 
a decrease of the neuronal population and this plays a role in depression and dementia in 
PD (Chan-Palay, 1991). A more recent study described the morphological and 
morphometric alterations of the locus coeruleus in patients who suffered from PD with 
normal cognitive function and in patients who suffered from PD associated with dementia, 
comparing them with normal controls and the morphological alterations of the synapses in 
cases of PD associated with dementia plead in favor of the importance of the normal circuits 
of locus coeruleus in cognitive functions (Baloyannis et al., 2006). Furthermore, it was shown 
that among 20 brain areas dopamine loss in PD was negatively correlated with healthy 
noradrenaline levels, with regions rich in noradrenaline spared from dopamine loss. The 
authors concluded that “…therapeutic approaches designed to enhance brain noradrenergic 
activity … should be considered as possible neuroprotective strategies in PD” (Tong et al., 
2006, p. 1727). Thus, the fact that D is a potent enhancer of the noradrenergic neurons is 
additional important factor which might substantially contribute in slowing the age-related 
decline of brain functions. 
Since on isolated substantia nigra of rats the special CAE effect of D is detectable already at 
10-14M concentration and in in vivo experiments 0.025 mg/kg D (1/10th of the dose which 
blocks MAO-B) is sufficient to keep the dopaminergic neurons in the midbrain on a higher 
activity level, and since decades of clinical experiences showed that the regular daily dose, 
10 mg D is very safe, the prophylactic administration of 1 mg D per day lends itself 
particularly well for life-long treatment.  
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9. Conclusion 
The catecholaminergic machinery, the noradrenergic and dopaminergic neuronal system in 
the brain plays a key role in the maintenance of vigilance, motivation, alerting and 
orientation, as well as in learning, sexual activity, drive motivated behavioral performances, 
cognition, etc. The dopaminergic system is the most rapidly aging neuronal system in the 
brain. Since the diagnosis of PD is the unequivocal proof that age-related irreversible 
deterioration of the nigrostriatal dopaminergic neuronal system has already surpassed a 
critical level in the patient, and the disease is incurable, prevention remains the only chance 
for the future to fight off PD. 
The development of D in 1964/1965 which became famous in 1971/1972 as the first selective 
inhibitor of MAO-B and started its carrier as a therapeutic agent in 1977 as the unique MAO-
B inhibitor which being free of the cheese effect could safely be combined with levodopa in 
PD and is at present registered in 64 countries and used to treat PD, AD and major 
depression, is a unique stimulant of catecholaminergic neurons in the brain. D is a 
derivative of methamphetamine, which is a long acting variant of PEA, the natural brain 
constituent. Both PEA and methamphetamine are known to act as releasers of 
catecholamines from their neuronal pool. D is the first PEA/methamphetamine-derivative 
free of the catecholamine releasing property and this change in the pharmacological 
spectrum ensured to discover that D is enhancing via a previously undetected mechanism 
the activity of the catecholaminergic neurons in the brain. This CAE effect of PEA which is 
exerted in much lower concentration than its catecholamine releasing effect remained 
undetected because the releasing effect hindered its detectability.  
The role of D in the discovery of the enhancer regulation was clarified in a monograph 
(Knoll, 2005). Data were presented showing that in the course of developmental longevity, 
from weaning until sexual maturity, a significantly higher level of enhancer regulation is 
operating in the catecholaminergic neurons. This mechanism is responsible for the 
exuberant physical strength and mental vigor in the uphill period of life. Sexual hormones 
terminate this period and bring back the enhancer regulation to the pre-weaning level. This 
mechanism terminates developmental longevity and constitutes the foundation of the 
transition from adolescence to adulthood. The postdevelopmental phase of life, the slow 
continuous aging process, the unfortunate common fate of all mature adults begins and is 
finally terminated by natural death. Since D as a safe CAE substance works against the slow 
age-related decline of the catecholaminergic neurons in the brain, prophylactic lifelong 
administration of 1 mg D per day is proposed to slow the natural aging process. 
The longevity studies performed with D furnished unequivocal evidence that life-long 
prophylactic treatment with D slowed significantly the age-related decline of the sexual 
performance and learning ability of animals and prolong their life. Furthermore, on the one 
hand, the retrospective analysis of the survival of patients treated with madopar alone 
(N=377) and with madopar plus D (N=564) showed that the supplementation of madopar 
with D significantly prolonged the survival of patients, and on the other hand, the 
DATATOP study showed that D-treatment slowed down the rate of deterioration of the 
human striatal dopaminergic system. These experimental and clinical findings guide the 
way for the long overdue study to select at least 60 year-old healthy males and females, treat 
half of the population with placebo and half with 1 mg D per day, and follow carefully the 
changes in their state of health until death. Since the decay of the catecholaminergic 
machinery with the passing of time plays an obviously important role in brain aging, and 
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there is unequivocal evidence that D slows the aging of the catecholaminergic system, 
prophylactic D-treatment will not only improve the quality of life in senescence but it seems 
to be a pharmacologically well-founded expectation that the prevalence of PD and AD 
might be significantly lower in the D-treated group than in the placebo-treated one. Over 60 
the number of the most common age-related neurodegenerative diseases, Parkinson’s and 
Alzheimer’s, start to increase because, in a sensitive part of the population the decay of some 
functionally key important neuronal systems surpass a critical level (like the dopaminergic 
machinery in case of PD), thus the maintenance of the enhancer regulation on a higher 
activity level may slow this process. Considering the rapid increase of the population over 
65, a collaborative implementation of the proposed clinical trial, which has a fair chance of 
success, is of greater importance than realized heretofore. 
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progresses despite the current therapies until the cell loss is so great that the quality of normal life is
compromised. The dopamine precursor levodopa is the most valuable drug currently available for the
treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around
five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the
mechanisms of degeneration and to develop disease modifying therapies.
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